Proxalutamide Reduces Hospitalization Rate in Mild-to-Moderate COVID-19 Female Patients: A Randomized Double-Blinded Placebo-Controlled Trial

The study evaluated the efficacy of proxalutamide, an antiandrogen, as a treatment for mild-to-moderate COVID-19 in females. The randomized, double-blind, placebo-controlled study involved 177 women, with 75 in the proxalutamide group and 102 in the placebo group. The primary outcome was hospitalization rates within 30 days of treatment. The results showed that the 30-day hospitalization rate was 2.7% in the proxalutamide group and 18.6% in the placebo group, indicating that proxalutamide reduced the hospitalization rate by 86% (p < 0.001). The study concluded that treatment of COVID-19 patients with proxalutamide in combination with standard care significantly reduced hospitalization rates, with no safety concerns reported.